In 2024, the Prize focused on the nexus between climate change and health, with the question: “How can economic policies incentivise environmentally sustainable innovation in the life sciences sector?

OHE presents an overview on the use of cost-effectiveness thresholds (CETs) in a number of selected countries in their decision-making process for health technology assessments (HTAs). In addition to ...

Adult vaccines can return up to 19 times their initial investment to society, when their significant benefits beyond the healthcare system are monetised.

Digital Health Technologies are a major trend in health care, and successfully adding them to the wider portfolio of health technologies requires coordinated involvement from various stakeholders.

In this report, we highlight the significance of prevention as a cost-effective and often cost-saving investment for public sector resources. Prevention, covering primary, secondary, and tertiary ...

In this report, we describe the design of a globally aligned, value-based, fully-delinked pull incentive, where payers provide manufacturers with a pre-specified subscription fee based on the value of ...

‘First-of-its-kind’ study shows that adult immunisation programmes return up to 19 times their initial investment when the full spectrum of benefits is valued The findings highlight the opportunity to ...

A biennial prize fund to promote thought leadership around the big questions affecting health economics. OHE’s educational mission is to support, sustain, and enhance the discipline of health ...

In this report, we investigate the theory and practice of value-based pricing in the pharmaceuticals industry, and provide recommendations for how implementation of value-based pricing can be enhanced ...

In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised under the same NICE process, a new OHE Consulting Report discusses the distinct ethical ...

In this report, commissioned and funded by Pfizer, we explore the extent to which previous OHE recommendations for the health technology assessment (HTA) of gene therapies are being achieved in nine ...

A recent issue of Value in Health contains the ISPOR Special Task Force Report on US Value Assessment Frameworks. In this blog post, we summarise the Task Force Report and pick up key points made in ...